Mindray at Arab Health 2011 - Analyst Blog

Leading Chinese medical devices maker Mindray Medical International Limited (MR) has announced that it will participate in Arab Health 2011, slated to be held in Dubai from January 24-27, 2011. Arab Health is the largest health care trade show in the Middle East with more than 2,700 exhibitors and around 66,000 visitors from across the globe having attended the event in 2010.

Mindray plans to showcase more than 50 devices from its three major product segments at Arab Health 2011. Key products to be featured include the V series patient monitoring system, WATO-EX 35 anesthesia machine and BS-800 chemistry analyzer. The company will also exhibit its upcoming hematology analyzer BC-6800, planned for launch this year.

Mindray reckons Arab Health 2011 as a major platform to demonstrate its expanding portfolio of high-quality products and its sustained R&D commitment to provide clinicians with the latest technology that enhances patient care. The company recently announced that it has met its product development goals for 2010, having launched 10 new products during the year.

Moreover, Mindray has divulged its pipeline strategy for 2011 highlighting its plans to beef up product innovation by lifting R&D investment. The company aims to introduce 7-10 new products during 2011 and the areas of product expansion include patient monitoring, defibrillator, anesthesia delivery and blood analysis.

With its operational headquarters in Shenzhen, China, Mindray is a global Chinese medical devices company operating through three segments. The company's products hold a roughly 40% share of the Chinese healthcare market.

Besides China, Mindray operates in North America, Europe and other Asian countries.  The company competes with global devices manufacturers such as General Electric (GE), Philips (PHG) and Siemens (SI).

Mindray has a strong position in the low and mid segments of the medical devices market in China and is poised to benefit from the solid fundamentals of the Chinese health care sector. Its new product development initiatives, expanding international footprint (and revenues) and solid sales infrastructure remain encouraging.

Although Mindray's strength is currently in the low and mid-end segments, the company is looking to carve a niche in the high-end markets. Moreover, Mindray is well positioned to benefit from the health care reforms in China. However, the company is exposed to intense competition-driven pricing pressure.  

 
GENL ELECTRIC (GE): Free Stock Analysis Report
 
MINDRAY MEDICAL (MR): Free Stock Analysis Report
 
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
 
SIEMENS AG-ADR (SI): Free Stock Analysis Report
 
Zacks Investment Research